



Aminoalkoxybiphenylnitriles as Histamine-3 Receptor Ligands

Ramin Faghih,* Wesley Dwight,[†] Anil Vasudevan, Jurgen Dinges, Scott E. Conner,[‡] Timothy A. Esbenshade, Youssef L. Bennani[§] and Arthur A. Hancock

Neuroscience-Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6123, USA

Received 17 June 2002; accepted 2 August 2002

Abstract—Biaryl nitrile amines were prepared and found to have high affinity and selectivity for human and rat histamine H₃ receptors.

© 2002 Elsevier Science Ltd. All rights reserved.

Histamine exerts a variety of physiological effects via four known distinct G-protein coupled receptors.¹ Histamine plays a major role in immediate hypersensitivity reactions following release from mast cells. The action of released histamine on airway and blood vessel smooth muscle accounts for the symptoms of the allergic response and is mediated by the H₁ receptor² and is blocked by classic antihistamines. Histamine is also an important regulator of gastric acid secretion through its action on parietal cells. These effects are mediated via the H₂ receptor³ and these are blocked by H₂ receptor antagonists. The third histamine receptor⁴ was first described as a presynaptic autoreceptor in the CNS controlling the synthesis and release of histamine. Recently, evidence suggesting the presence of H₃ receptors located presynaptically on hetero-receptors has emerged. The bulk of medicinal chemistry with respect to H₃ receptor ligands is related to their potential to treat CNS disorders. Some H₃ antagonists have been studied in models of learning, memory and schizophrenia.⁵ Therefore a H₃ antagonist with high receptor selectivity and good BBB penetration may offer a new approach for the treatment of a wide range of CNS disorders. Recently we have described the SAR of a new series of non-imidazole containing H₃ blockers⁶ (Fig. 1). In order to expand the SAR to provide a new isostere for the ketone moiety seen in Figure 1 and to optimize lipophilicity for CNS penetration, we prepared a series of biaryl piperazine amides.

We wish to report herein on the preparation and SAR of this series. Commercially available 4-bromophenol was treated with 1-bromo-3-chloropropane in the presence of K₂CO₃ in refluxing 2-butanone for 24 h (Scheme 1). The resulting *O*-propyl chloride (obtained in ~95% yield) was further treated, without purification, with piperazine-1-carboxylic acid ethyl ester to give the desired compounds (**1**) in 70–90% yield after silica gel chromatography. Treatment of **1** under Suzuki or Stille cross coupling reactions leads to the desired *N*-ethylcarbamate piperazine derivatives. These were assayed in a binding experiment using rat cortex in order to probe the SAR of the H₃ receptor.

Data from Table 1 indicate weak to moderate affinity for the rat H₃R, especially when compared with their alkylketone homologues.⁶ However, based on favorable physicochemical properties and moderate potency, the biarylnitrile **4** was selected for further modification. The basic piperazine in **4** was replaced with a variety of amines (Scheme 2): morpholine, pyrrolidine, homopiperazine, 4-(*R*)-aminopyrrolidine, pyrrolidine[3,4-*c*]pyrrolidine,⁹ etc., this time with significant improvement in affinity at the rat H₃R (e.g., compd **21** and **32** with p*K*_i of 8.01 and 8.19, Table 2) when compared to similar transformations in the alkylketone series.⁶ Small alkyl-substituted pyrrolidines and piperidines provided for an enhanced affinity at the rat H₃R. From the data





Figure 1.

*Corresponding author. Fax: +1-847-937-4143; e-mail: ramin.faghih@abbott.com


[†]Present address: Neurocrine Biosciences, San Diego, CA, USA.

[‡]Present address: Eli Lilly, Indianapolis, IN, USA.

[§]Present address: Athersys Inc., Cleveland, OH, USA



Scheme 1. (a) $\text{Cl}-(\text{CH}_2)_3-\text{Br}$, K_2CO_3 , 2-butanone, reflux 24 h; (b): $\text{N}-\text{COOEt}$ -piperazine, $\text{KI}/\text{K}_2\text{CO}_3$, 2-butanone, reflux 72 h; (c): Suzuki or Stille, $\text{PdCl}_2(\text{Ph}_3)_2$, DMF, 24 h, 40–75%.



Scheme 2. (a) $\text{Cl}-(\text{CH}_2)_3-\text{Br}$, K_2CO_3 , 2-butanone, reflux 24 h, 98%; (b) amines, $\text{KI}/\text{K}_2\text{CO}_3$, 2-butanone, reflux 72 h, 60–90%.

Table 1. Binding affinities^a (pK_i) at rat cortical H_3 and human H_1 and H_2 receptors^{7,8}

Compd ^b :R	H_3	H_1	H_2	R	H_3	H_1	H_2
2: 4'-Br-Ph	6.95	6.74	5.78	9: 4-Pyridine-4	5.56	5.43	4.24
3: 4'-OMe-Ph	6.59	6.45	4.00	10: 4-Thiophen-2	6.64	6.35	4.48
4: 4'-CN-Ph	7.55	6.80	4.54	11: 4-Thiopen-3	6.68	6.12	4.01
5: 4'-Cl-Ph	6.72	6.45	5.25	12: 4'-OCF ₃ -Ph	6.62	6.36	5.44
6: 4'-NO ₂ -Ph	7.01	7.09	5.08	13: 4'-CN-2'-Me-Ph	6.99	7.56	5.40
7: 2'-NO ₂ -Ph	6.21	6.79	5.12	14: 4-Pyrrol	7.25	6.30	4.89
8: 3'-CN-Ph	5.95	6.42	4.62	15: 4-Imidazol	6.06	5.83	4.16

^aValues were estimated from at least three separate competition experiments ($\text{SEM} \leq 0.2$).

^bSatisfactory ^1H NMR, MS spectra and elemental analyses were obtained for all new compounds.

in Table 2 the stereoselective nature of the H_3 receptor (e.g., compound **27** statistically significantly more

potent than the *S*-enantiomer **28** at both rat ($P=0.14$, unpaired *t*-test, RS/1) and human [$P=0.04$, unpaired *t*-test, RS/1, see below] receptors) is noteworthy.

While this work was in progress Lovenberg and colleagues reported the cloning of the human H_3 receptor.¹⁰ Subsequently, both the guinea pig and rat H_3 receptor orthologues have also been successfully cloned.¹¹ We assayed using human cloned H_3 receptors in binding experiments selected examples of the biarylnitrile series to explore their SAR at the human receptor (Table 3).

Some interesting observations can be made from these results: several *N*-ethylcarbamate piperazine compounds such as **4** and **14** were an order of magnitude less potent at the human recombinant receptor than at the native rat receptor (pK_i of 6.00 versus 7.55 or 6.00 versus 7.25 at human or rat H_3 , respectively). The rat

Table 2. Binding affinities^a (pK_i) at rat cortical H_3 and human H_1 and H_2 receptors

Amines	H_3	H_1	H_2	Amines	H_3	H_1	H_2
16: Piperazine	6.23	5.05	4.64	26: Pyrrolidine	7.38	5.30	4.17
17: Homopiperazine	7.87	5.41	5.11	27: 3-(<i>R</i>)-OH-Pyrrolidine	7.29	5.35	4.77
18: Morpholine	7.60	5.49	4.42	28: 3-(<i>S</i>)-OH-Pyrrolidine	6.90	5.25	4.72
19: 2-Me-Piperidine	7.64	5.46	4.73	29: 3-(<i>R</i>)-NH ₂ -Pyrrolidine	7.20	4.86	5.13
20: 3-Me-Piperidine	7.58	6.56	4.93	30: 3-(<i>R</i>)-NHMe-Pyrrolidine	7.53	5.43	5.00
21: 4-Me-Piperidine	8.01	6.37	5.04	31: 3-(<i>R</i>)-NMe ₂ -Pyrrolidine	7.87	5.72	5.00
22: 3-OH-Piperidine	7.09	5.11	4.89	32: 2,5-(<i>R,R</i>)-di-Me-Pyrrolidine	8.19	6.25	5.04
23: 4-OH-Piperidine	7.50	6.24	5.00	33: 3-(<i>R</i>)-Me-Pyrrolidine-3-ol	7.81	5.41	4.82
24: 2,6-di-Me-Piperidine	7.79	5.40	4.62	34: Pyrrolidine[3,4- <i>c</i>]Pyrrolidine	7.18	5.54	4.91
25: 4-NH ₂ -Piperidine	6.89	5.45	4.47				

^aSee corresponding footnote in Table 1.

Table 3. Binding affinities^a (pK_i) at human cloned H_3 receptors¹⁰

Compd	h H_3	Compd	h H_3	Compd	h H_3
4	6.00	21	7.86	28	7.71
14	6.00	22	7.52	29	8.21
16	6.93	23	6.91	30	8.07
17	8.08	24	8.67	31	8.56
18	7.44	25	6.70	32	9.17
19	8.15	26	8.14	33	8.39
20	8.77	27	8.08	34	7.82

^aSee corresponding footnote in Table 1.

H₃ receptor is highly homologous to the human receptor, although two amino acid residues differences located in the vicinity of the aspartate residue (Asp¹¹⁴) in the TM3 helices important for the binding of positively charged biogenic amines could help explain these differences in binding between the two species. Ligneau and colleagues also observed these types of differences in binding with a number of H₃ antagonists.¹² In contrast, the biaryl nitrile amines are displaying a reverse preference, that is, equipotent or an order of magnitude more potent at the human cloned receptor than at the rat receptor.

In summary we have discovered highly potent ligands for both human and rat H₃ receptors, with several exemplary compounds demonstrating an approximate 10-fold higher affinity for the human H₃ receptor. These results differ from a number of imidazole-based H₃ antagonists that show a weaker affinity for human, compared to rat H₃ receptors, such as thioperamide, ciproxifan or GT-2331.¹³ The high affinity of some of these compounds (e.g., compd 31 or A-331440) for the human receptor, coupled with other favorable physiological and pharmacodynamic properties (to be described elsewhere),¹⁴ suggest that such compounds may have therapeutic potential in various human diseases.

References and Notes

- (a) Leurs, R.; Watanabe, T.; Timmerman, H. *Trends Pharmacol. Sci.* **2001**, *22*, 337. (b) Hough, B. L. *Mol. Pharmacol.* **2001**, *59*, 415.
- (a) Ash, A. S. F.; Schild, H. O. *Br. J. Pharmacol.* **1966**, *27*, 427. (b) Kinsolving, C. R.; Munro, N. L.; Carr, A. A. *Pharmacologist* **1973**, *15*, 221.
- Black, J. W.; Duncan, W. A. M.; Durant, G. J.; Ganellin, C. R.; Parsons, E. M. *Nature (London)* **1972**, *236*, 385.
- (a) Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. *Nature (London)* **1983**, *302*, 832. (b) Arrang, J.-M.; Garbarg, M.; Lancelot, J.-C.; Lecomte, J.-M.; Pollard, H.; Robba, M.; Schunack, W.; Schwartz, J.-C. *Nature (London)* **1987**, *327*, 117. (c) Leurs, R.; Timmerman, H., Eds. *The Histamine H₃ Receptor A Target For New drugs, Pharmacochimistry Library*, Vol. 30; Elsevier, Amsterdam, 1998. (d) Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. *Trends Pharmacol. Sci.* **1998**, *19*, 177. (e) Lovenberg, T. W.; Roland, B. L.; Wilson, S. J.; Jiang, X.; Pyati, J.; Huvar, A.; Jackson, M. R.; Erlander, M. G. *Mol. Pharmacol.* **1999**, *55*, 1101. (f) Lovenberg, T. W.; Pyati, J.; Chang, H.; Wilson, S. J.; Erlander, M. G. *J. Pharmacol. Exp. Ther.* **2000**, *293*, 771. (g) Leurs, R.; Hoffmann, M.; Wieland, K.; Timmerman, H. *Trends Pharmacol. Sci.* **2000**, *21*, 11.
- (a) Stark, H.; Schlicker, E.; Schunack, W. *Drugs Fut.* **1996**, *21*, 507. (b) Tozer, M. J.; Kalindjian, S. B. *Exp. Opin. Ther. Patents* **2000**, *10*, 1045. (c) Halpern, M. T. *Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs* **1999**, *1*, 524. (d) Ali, S. M.; Tedford, C. E.; Gregory, R.; Handley, M. K.; Yates, S. L.; Hirth, W. W.; Phillips, J. G. *J. Med. Chem.* **1999**, *42*, 903. (e) Fox, G. B.; Pan, J. B.; Esbenshade, T. A.; Bennani, Y. L.; Black, L. A.; Faghih, R.; Hancock, A. A.; Decker, M. W. *Behav. Brain Res.* **2002**, *131*, 151.
- Faghih, R.; Dwight, Gentles, R.; Phelan, K.; Esbenshade, T.; Ireland, L.; Miller, T.; Kang, C.-H.; K.; Fox, G.; Gopalakrishnan, S. M.; Hancock, A. A.; Bennani, Y. L. *Bioorg. Med. Chem. Lett.* In press.
- Hancock, A. A.; Esbenshade, T. E. In *Current Protocols In Pharmacology*; Enna, Williams, Ferkany, Kenakin, Porsolt and Sullivan, Eds.; John Wiley & Sons, 2000; Vol. 1.19, pp 1–22.
- Garbarg, M.; Arrang, J.-M.; Rouleau, A.; Ligneau, X.; Tuong, M. D.; Schwartz, J.-C.; Ganellin, C. R. *J. Pharmacol. Exp. Ther.* **1992**, *263*, 304.
- Weinges, K.; Spaening, R. *Chem. Ber.* **1968**, *101*, 3010.
- Lovenberg, T. W.; Roland, B. L.; Wilson, S. J.; Jiang, X.; Pyati, J.; Huvar, A.; Jackson, M. R.; Erlander, M. G. *Mol. Pharmacol.* **1999**, *55*, 1101.
- (a) Tardivel-Lacombe, J.; Rouleau, A.; Heron, A.; Morisset, S.; Pillot, C.; Cochois, V.; Schwartz, J.-C.; Arrang, J.-M. *Neuroreport* **2000**, *11*, 755. (b) Drutel, G.; Peitsaro, N.; Karlstedt, K.; Wieland, K.; Smit, M. J.; Timmerman, H.; Panula, P.; Leurs, R. *Mol. Pharmacol.* **2000**, *59*, 1.
- Ligneau, X.; Morisset, S.; Tardivel-Lacombe, J.; Gbahou, F.; Ganellin, C. R.; Stark, H.; Schunack, W.; Schwartz, J.-C.; Arrang, J.-M. *Brit. J. Pharmacol.* **2000**, *131*, 1247.
- (a) Denny, L. I.; Parihar, A. S.; Miller, T. R.; Kang, C. H.; Bennani, Y. L.; Krueger, K. M.; Esbenshade, T. A.; Hancock, A. A. *Eur. J. Pharmacol.* **2001**, *433*, 141. (b) Lovenberg, T. W.; Pyati, J.; Chang, H.; Wilson, S. J.; Erlander, M. G. *J. Pharmacol. Exp. Ther.* **2000**, *293*, 771. (c) Ligneau, X.; Morisset, S.; Tardivel-Lacombe, J.; Gbahou, F.; Ganellin, C. R.; Stark, H.; Schunack, W.; Schwartz, J.-C.; Arrang, J.-M. *Brit. J. Pharmacol.* **2000**, *131*, 1247.
- (a) Bush, E. N.; Shapiro, R.; Nuss, M.; Knourek-Segel, V.; Wilcox, D.; Droz, B.; Faghih, R.; Bennani, Y.; Esbenshade, T.; Jacobson, P. B.; Hancock, A. A. *Abstracts, American Diabetes Association* **2002**. (b) Krueger, K. M.; Kang, C. H.; Miller, T.; Witte, D.; Faghih, R.; Bennani, Y.; Esbenshade, T. A.; Hancock, A. *Pharmacologist* **2002**, *44* (Suppl 1), A196. (c) Hancock, A.; Fox, G.; Bush, E.; Shapiro, R.; Nuss, M.; Knourek-Segel, V.; Wilcox, D.; Droz, B.; Jacobson, P.; Bennani, Y.; Esbenshade, T.; Faghih, R. *Pharmacologist* **2002**, *44* (Suppl 1), A157.